You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 16, 2024

METHYLIN ER Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Methylin Er, and when can generic versions of Methylin Er launch?

Methylin Er is a drug marketed by Specgx Llc and is included in one NDA.

The generic ingredient in METHYLIN ER is methylphenidate hydrochloride. There are thirty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Methylin Er

A generic version of METHYLIN ER was approved as methylphenidate hydrochloride by SPECGX LLC on November 27th, 1998.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for METHYLIN ER?
  • What are the global sales for METHYLIN ER?
  • What is Average Wholesale Price for METHYLIN ER?
Drug patent expirations by year for METHYLIN ER
Recent Clinical Trials for METHYLIN ER

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Nicoleta StoiceaPhase 1
Boston Children's HospitalPhase 1
Dana-Farber Cancer InstitutePhase 1

See all METHYLIN ER clinical trials

Pharmacology for METHYLIN ER

US Patents and Regulatory Information for METHYLIN ER

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc METHYLIN ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 075629-001 May 9, 2000 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Specgx Llc METHYLIN ER methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 075629-002 May 9, 2000 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.